On 21 July 2026, the MHRA announced approval of new versions of Clenil Modulite 100 micrograms and 200 micrograms inhalers containing beclometasone dipropionate. The agency described the approval as the world's first authorisation of pressurised metered-dose inhalers using the next-generation propellant HFA-152a.
The propellant is not the active medicine. It is used to deliver the inhaled dose. The MHRA said the new versions will be available in the UK later in 2026, while the current versions continue to be available to patients in the meantime.
Why this approval is notable
The headline is environmental, but the operational story is broader. The MHRA stated that no changes have been made to the active ingredient, recommended doses or therapeutic indications, and that evidence supports comparable performance with the currently authorised products while maintaining quality, safety and clinical benefit.
For pharmacies, wholesalers and healthcare organisations, this kind of product change creates practical questions long before stock moves through the supply chain.
Supply-chain questions to consider
When a lower-carbon version of an established medicine enters the market, teams may need to review:
- product codes, pack information and purchasing systems;
- updated Summary of Product Characteristics and Patient Information Leaflet publication;
- how current and new versions will be distinguished in stock systems;
- what healthcare professionals need to know before patient-facing conversations;
- whether any storage, handling or documentation requirements change;
- how sustainability goals interact with continuity of supply.
It is important not to turn a regulatory approval into unsupported substitution advice. Product choice and patient counselling remain clinical and professional matters. The wholesale role is to support accurate, traceable and compliant supply.
Sustainability is becoming part of medicines planning
The approval shows that environmental performance can sit alongside established medicine standards. As the market changes, supply partners will need to handle new presentations carefully, avoid confusion between product versions and keep documentation aligned with the approved product information.
Logan Pharmaceuticals' pharmaceutical services and quality pages set out the broader standards behind regulated wholesale supply. For product-specific availability and documentation questions, contact the Logan team directly.
Sources
Primary source: MHRA: MHRA approves world's first lower-carbon beclometasone inhalers for patients with asthma, accessed 30 July 2026.